KEGG   DRUG: AlefaceptHelp
Entry
D02800                      Drug                                   

Name
Alefacept (USAN/INN);
Amevive (TN)
Formula
C3264H5002N840O988S20
Exact mass
72414.14
Mol weight
72458.9759
Sequence
FSQQIYGVVY GNVTFHVPSN VPLKEVLWKK QKDKVAELEN SEFRAFSSFK NRVYLDTVSG
SLTIYNLTSS DEDEYEMESP NITDTMKFFL YVDKTHTCPP CPAPELLGGP SVFLFPPKPK
DTLMISRTPE VTCVVVDVSH EDPEVKFNWY VDGVEVHNAK TKPREEQYNS TYRVVSVLTV
LHQDWLNGKE YKCKVSNKAL PAPIEKTISK AKGQPREPQV YTLPPSRDEL TKNQVSLTCL
VKGFYPSDIA VEWESNGQPE NNYKTTPPVL DSDGSFFLYS KLTVDKSRWQ QGNVFSCSVM
HEALHNHYTQ KSLSLSPGK
(Dimer; Disulfide bridge:98-98', 101-101', 133-193, 239-297, 133'-193', 239'-297')
  Type
Peptide
Remark
ATC code: L04AA15
Efficacy
Antipsoriatic, Immunosuppressant
Comment
Alefacept is a fusion protein combining the first extracellular domain of LFA3 [HSA:965] [KO:K06492] with constant regions, CH2 and CH3.
LFA-3Ig
Treatment of plaque psoriasis
Target
CD58 (LFA3) [HSA:965] [KO:K06492]
  Pathway
hsa04514  Cell adhesion molecules (CAMs)
Interaction
Drug interaction
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
  L04 IMMUNOSUPPRESSANTS
   L04A IMMUNOSUPPRESSANTS
    L04AA Selective immunosuppressants
     L04AA15 Alefacept
      D02800  Alefacept (USAN/INN)
Target-based classification of drugs [BR:br08310]
 Cell surface molecules and ligands
  Cell adhesion molecules: Ig superfamiy
   CD2 family
    CD58 (LFA3)
     D02800  Alefacept (USAN/INN)
BRITE hierarchy
Other DBs
CAS: 222535-22-0
PubChem: 17396958
DrugBank: DB00092
LinkDB All DBs

» Japanese version   » Back

DBGET integrated database retrieval system